T-1377 Tofacitinib, Free Base, >99%

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 2 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

CPS-117 CPS-116 CPS-115 CPS-114 CPS-104

View the SDS for this product

• More than 250 labs worldwide have purchased Tofacitinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
• This product was previously Cat. No. C-1377, CP-690550, and was also previously named Tasocitinib under the current Cat. No. T-1377
• Tofacitinib is a novel Janus kinase 3 (JAK3) inhibitor. JAK3 is a critical cytoplasmic tyrosine kinase in the signaling pathways of multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are associated with various T cell functions
• Preclinical and clinical data strongly support that Tofacitinib, as an immunosuppressant, prevents organ transplant rejection and alleviates the symptoms of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriasis. West, K. "CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders." Curr. Opin. Investig. Drugs 10: 491-504 (2009)
• Tofacitinib showed greater antiproliferative and pro-apoptotic activity against murine multipotent factor-dependent cell Patersen-erythropoietin receptor (FDCP-EpoR) cells harboring JAK2(V617F) compared with JAK2(WT). Manshouri, T., et al. "The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation." Cancer Sci. 99: 1265-1273 (2008)
• JAK3 plays an important role in pulmonary eosinophilia in the allergic mouse model. Tofacitinib, as a JAK3 inhibitor, represents a potential therapy for treatment of allergic conditions associated with airway eosinophilia including asthma and rhinitis. Kudlacz, E., et al. "The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia." Eur. J. Pharmacol. 582: 154-161 (2008)
• Tofacitinib was evaluated in murine collagen-induced (CIA) and rat adjuvant-induced (AA) models of rheumatoid arthritis (RA). Tofacitinib dose-dependently reduced endpoints of disease in both RA models. The compound also inhibited inflammatory cell influx and joint damage. Milici, A.J., et al. "Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis." Arthritis Res. Ther. 10: R14 (2008).
• Tofacitinib effectively blocked allograft vasculopathy in the rat model of aorta transplantation by inhibiting JAK3. Rousvoal, G., et al. "Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy." Transpl. Int. 19: 1014-1021 (2006).
• Combination treatment of Tofacitinib with mycophenolate mofetil (MMF) significantly improved allograft survival in nonhuman primates compared to treatment with MMF alone. Borie, D.C., et al. "Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates." Transplantation 80: 1756-1764 (2005).
• Tofacitinib (as the citrate salt) is the active ingredient in the drug product sold under the trade name Xeljanz®. This drug is currently approved in at least one country for use in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. NOTE:  THE TOFACITINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT XELJANZ®, AND IS NOT FOR HUMAN USE.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.
• Please see also our other standard immunosuppressant products:
  A-1040 Ascomycin
  C-6000 Cyclosporin A
  E-4040 Everolimus
  F-4633 Fingolimod Hydrochloride Salt
  F-4900 FK-506
  R-5000 Rapamycin
  T-8040 Temsirolimus
  T-1399 Tofacitinib,Citrate